AstraZeneca will publish up-to-date results from its latest COVID-19 vaccine trial within 48 hours after U.S. health officials said the drugmaker’s analysis of the shot’s efficacy may not have been based on all the available data.
The rare public rebuke marks the latest setback for the vaccine which was hailed as a milestone in the fight against the COVID-19 pandemic but has since been dogged by questions over its effectiveness and possible side effects.
AstraZeneca said results it published on Monday giving the shot an efficacy rate of 79% were based on an interim analysis of data through Feb. 17 and it would now “immediately engage” with the panel monitoring the trial to share its full analysis.
The Anglo-Swedish drugmaker said on Tuesday it had reviewed the preliminary assessment of its full, or primary, analysis and found it to be consistent with the interim report.
Its shares were down 2.5% in London trading.
The U.S. National Institute for Allergy and Infectious Diseases (NIAID)…
